Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 

Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

Macular Degeneration Research - Current Award

Photo Pending

Dwight Stambolian, M.D., Ph.D.

University of Pennsylvania
Philadelphia, PA

Title: Potential Therapy of Age-Related Macular Degeneration with Small Molecules
Non-Technical Title: Small molecule therapy for Macular Degeneration

Duration: April 1, 2008 - June 30, 2010
Award Type: Standard
Award Amount: $100,000


Summary:

This project is looking for a small molecule which can penetrate the eye and diminish the eye inflammation that occurs in AMD. If successful, this small molecule can be administered at the earlier stages of AMD to halt progression to the later stages and eventual blindness. In order to identify such a molecule, we will screen a small molecule library and confirm its efficacy in a test tube before moving onto animal models.

Details:

Current treatments for AMD do not restore vision. In wet AMD, treatment is directed at the terminal stages making it impossible to return vision to 20/20. For the dry type, the only treatment is a special vitamin preparation that is only effective in slowing the progression of AMD in some people. The researchers are investigating a small molecule that can penetrate the eye and diminish the eye inflammation that occurs in AMD. If successful, this small molecule could be administered in the earlier stages of AMD to halt disease progression and prevent blindness. They will identify such a molecule by screening a small molecule library and then will confirm its efficacy in a test tube before moving onto animal models.